Adaptive Biotechnologies Corp
ADPT11.980USD
+1.330+12.49%
Close 06/25, 16:00（ET）Quotes delayed by 15 min
1.82BMarket Cap
LossP/E TTM
More Details of Adaptive Biotechnologies Corp Company
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Company Info
Ticker SymbolADPT
Company nameAdaptive Biotechnologies Corp
IPO dateJun 27, 2019
Founded at2009
CEOMr. Chad M. Robins
Number of employees619
Security typeOrdinary Share
Fiscal year-endJun 27
Address1165 Eastlake Ave E
CitySEATTLE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code98109
Phone12066590067
Websitehttps://www.adaptivebiotech.com
Ticker SymbolADPT
IPO dateJun 27, 2019
Founded at2009
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Chad M. Robins
Mr. Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.10M
-4.49%
Ms. Susan Bobulsky
Ms. Susan Bobulsky
Chief Commercial Officer - MRD
Chief Commercial Officer - MRD
347.24K
+37.09%
Mr. Francis Lo
Mr. Francis Lo
Chief People Officer
Chief People Officer
332.85K
+31.17%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Lead Independent Director
Lead Independent Director
209.30K
+8.24%
Dr. Sharon Benzeno, Ph.D.
Dr. Sharon Benzeno, Ph.D.
Chief Commercial Officer - Immune Medicine
Chief Commercial Officer - Immune Medicine
95.93K
-15.18%
Dr. Katey Einterz Owen, Ph.D.
Dr. Katey Einterz Owen, Ph.D.
Independent Director
Independent Director
57.23K
+42.41%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Independent Director
Independent Director
54.30K
+41.54%
Mr. Kyle Piskel
Mr. Kyle Piskel
Chief Financial Officer
Chief Financial Officer
47.39K
-3.91%
Ms. Karina Calzadilla
Ms. Karina Calzadilla
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Ms. Julie Rubinstein
Ms. Julie Rubinstein
President, Chief Operating Officer
President, Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Chad M. Robins
Mr. Chad M. Robins
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
2.10M
-4.49%
Ms. Susan Bobulsky
Ms. Susan Bobulsky
Chief Commercial Officer - MRD
Chief Commercial Officer - MRD
347.24K
+37.09%
Mr. Francis Lo
Mr. Francis Lo
Chief People Officer
Chief People Officer
332.85K
+31.17%
Mr. Peter M. Neupert
Mr. Peter M. Neupert
Lead Independent Director
Lead Independent Director
209.30K
+8.24%
Dr. Sharon Benzeno, Ph.D.
Dr. Sharon Benzeno, Ph.D.
Chief Commercial Officer - Immune Medicine
Chief Commercial Officer - Immune Medicine
95.93K
-15.18%
Dr. Katey Einterz Owen, Ph.D.
Dr. Katey Einterz Owen, Ph.D.
Independent Director
Independent Director
57.23K
+42.41%
Revenue Breakdown
Currency: USDUpdated: Sun, Apr 6
Currency: USDUpdated: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
MRD revenue
145.53M
81.32%
Immune meidicine revenue
33.43M
18.68%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
MRD revenue
145.53M
81.32%
Immune meidicine revenue
33.43M
18.68%
Shareholding Stats
Updated: Wed, Jun 11
Updated: Wed, Jun 11
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Viking Global Investors LP
19.74%
Rubric Capital Management LP
8.63%
The Vanguard Group, Inc.
7.32%
BlackRock Institutional Trust Company, N.A.
6.45%
Columbia Threadneedle Investments (US)
4.27%
Other
53.59%
Shareholders
Shareholders
Proportion
Viking Global Investors LP
19.74%
Rubric Capital Management LP
8.63%
The Vanguard Group, Inc.
7.32%
BlackRock Institutional Trust Company, N.A.
6.45%
Columbia Threadneedle Investments (US)
4.27%
Other
53.59%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
53.09%
Investment Advisor
23.82%
Hedge Fund
17.68%
Individual Investor
2.66%
Research Firm
2.15%
Private Equity
0.68%
Venture Capital
0.40%
Bank and Trust
0.30%
Pension Fund
0.28%
Institutional Shareholding
Updated: Sat, Feb 22
Updated: Sat, Feb 22
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
476
143.19M
94.26%
-9.97M
2024Q4
481
143.31M
96.47%
-18.10M
2024Q3
478
143.38M
97.20%
-27.99M
2024Q2
486
149.83M
101.63%
-16.40M
2024Q1
506
146.67M
99.58%
-10.66M
2023Q4
529
145.23M
100.12%
-16.05M
2023Q3
531
142.64M
98.54%
-11.65M
2023Q2
545
137.84M
95.31%
-15.76M
2023Q1
577
135.96M
94.24%
-11.97M
2022Q4
616
132.93M
92.90%
-17.07M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Viking Global Investors LP
29.99M
20.19%
--
--
Dec 31, 2024
Rubric Capital Management LP
14.60M
9.83%
+200.00K
+1.39%
Dec 31, 2024
The Vanguard Group, Inc.
10.69M
7.19%
+47.48K
+0.45%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
9.81M
6.6%
+55.67K
+0.57%
Dec 31, 2024
Nikko Asset Management Co., Ltd.
6.83M
4.6%
-900.75K
-11.65%
Dec 31, 2024
ARK Investment Management LLC
9.42M
6.34%
-2.18M
-18.77%
Dec 31, 2024
Millennium Management LLC
6.29M
4.24%
-3.11M
-33.06%
Dec 31, 2024
Aristotle Atlantic Partners, LLC
2.89M
1.94%
-114.50K
-3.82%
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
ARK Genomic Revolution ETF
4.33%
ROBO Global Healthcare Technology & Innovation ETF
1.82%
Franklin Genomic Advancements ETF
1.53%
First Trust Small Cap Growth AlphaDEX Fund
0.84%
Invesco NASDAQ Future Gen 200 ETF
0.7%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.49%
Invesco Dorsey Wright SmallCap Momentum ETF
0.49%
First Trust Small Cap Core Alphadex Fund
0.41%
iShares Micro-Cap ETF
0.2%
Invesco Nasdaq Biotechnology ETF
0.14%
View more
ARK Genomic Revolution ETF
Proportion4.33%
ROBO Global Healthcare Technology & Innovation ETF
Proportion1.82%
Franklin Genomic Advancements ETF
Proportion1.53%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.84%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.7%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.49%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.49%
First Trust Small Cap Core Alphadex Fund
Proportion0.41%
iShares Micro-Cap ETF
Proportion0.2%
Invesco Nasdaq Biotechnology ETF
Proportion0.14%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
